CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)
- Conditions
- Interventions
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 95
- Registration Number
- NCT05830071
- Locations
- 🇺🇸
PAREXEL Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients with Fabry Disease
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 18
- Registration Number
- NCT05710692
- Locations
- 🇯🇵
Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan
🇯🇵Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵University of the Ryukyu Hospital, Nishihara, Okinawa, Japan
PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)
- Conditions
- Interventions
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 25000
- Registration Number
- NCT05652439
- Locations
- 🇬🇧
Clinical Practice Research Datalink (CPRD), London, United Kingdom
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT05513950
- Locations
- 🇲🇰
PHI University Clinic of Pulmonology and Allergology, Skopje, North Macedonia
🇺🇦Medical Center of Limited Liability Company "Arensia Exploratory Medicine", department of Clinical Trials, Kyiv, Ukraine
🇬🇧Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 25
- Registration Number
- NCT05472662
- Locations
- 🇬🇧
Medicine Evaluation Unit Limited, Manchester, United Kingdom
PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT05431426
- Locations
- 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT05373953
- Locations
- 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 610
- Registration Number
- NCT05292586
- Locations
- 🇺🇸
Chiesi Clinical Trial Site 840833, Houston, Texas, United States
🇺🇸Chiesi Clinical Trial Site 840819, Miami, Florida, United States
🇺🇸Chiesi Clinical Trial Site 840887, Miami, Florida, United States
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion
- Conditions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 23
- Registration Number
- NCT05186324
- Locations
- 🇺🇸
#06, Dallas, Texas, United States
🇧🇪#22, Antwerp, Belgium
🇺🇸#03, Atlanta, Georgia, United States
CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD
- Conditions
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 106
- Registration Number
- NCT05097014
- Locations
- 🇩🇪
PAREXEL International GmbH Early Phase Clinical Unit Berlin, Berlin-Spandau, Berlin Spandauer Damm, Germany